SCHEMBL23456058

SCHEMBL23456058

COc1ccc(C(OC[C@H]2C[C@@H](Oc3cc(Cl)ncn3)[C@H](F)[C@@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 2/20 0.37
▸ SLC6A11 P48066 6/20 0.34
▸ SLC6A1 P30531 3/20 0.34
▸ SLC6A12 P48065 2/20 0.32
▸ NAE1 Q13564 4/20 0.32
▸ UBA3 Q8TBC4 4/20 0.32
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ SLC5A1 P13866 1/20 0.31
▸ SLC5A2 P31639 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ SLC6A13 Q9NSD5 1/20 0.30
▸ HCRTR1 O43613 1/20 0.30
▸ HCRTR2 O43614 1/20 0.30
▸ FFAR4 Q5NUL3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23456008 0.86 TYMP (0.36) TYMPSLC6A11SLC6A1SLC5A1SLC5A2
SCHEMBL23456114 0.82 NAE1 (0.37) TYMPSLC6A11SLC6A1NAE1UBA3
SCHEMBL23456064 0.74 SLC5A1 (0.33) SLC5A1SLC5A2
SCHEMBL23455991 0.73 TYMP (0.37) TYMPSLC6A11SLC6A1NAE1UBA3
SCHEMBL23456015 0.71 TYMP (0.37) TYMPSLC6A11SLC6A1NAE1UBA3
SCHEMBL23456613 0.70 EGFR (0.48) NAE1UBA3
SCHEMBL30960669 0.70 EGFR (0.48) NAE1UBA3
SCHEMBL23455989 0.69 NAE1 (0.40) TYMPSLC6A11SLC6A1NAE1UBA3
SCHEMBL6414906 0.68 SLC6A11 (0.51) SLC6A11SLC6A1SLC6A12MEN1TP53
SCHEMBL6409688 0.68 SLC6A11 (0.51) SLC6A11SLC6A1SLC6A12MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054512-B2 Sting modulator compounds, and methods of making and using TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-08-06 — — US disclosed
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-27 — — US disclosed
US-11542293-B2 Sting modulator compounds, and methods of making and using TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-03 — — US disclosed
EP-3707151-B1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICALS CO (JP) 2022-01-05 — — EP disclosed
US-20210171565-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542293-B2 Sting modulator compounds, and methods of making and using STING1, CGAS, MAVS TYMP 1316/4885SLC6A11 3399/4885SLC6A1 3437/4885
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING STING1, CGAS, MAVS TYMP 1316/4885SLC6A11 3399/4885SLC6A1 3437/4885
US-12054512-B2 Sting modulator compounds, and methods of making and using STING1, CGAS, MAVS TYMP 1316/4885SLC6A11 3399/4885SLC6A1 3437/4885
US-20210171565-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING STING1, CGAS, MAVS TYMP 1316/4885SLC6A11 3399/4885SLC6A1 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback